The estimated Net Worth of Purnanand D Sarma is at least 809 千$ dollars as of 25 May 2021. Dr Sarma owns over 10,500 units of Immunome stock worth over 151,830$ and over the last 4 years he sold IMNM stock worth over 0$. In addition, he makes 657,442$ as Pres、 CEO & Director at Immunome.
Dr has made over 1 trades of the Immunome stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 10,500 units of IMNM stock worth 193,305$ on 25 May 2021.
The largest trade he's ever made was buying 10,500 units of Immunome stock on 25 May 2021 worth over 193,305$. On average, Dr trades about 2,625 units every 0 days since 2021. As of 25 May 2021 he still owns at least 10,500 units of Immunome stock.
You can see the complete history of Dr Sarma stock trades at the bottom of the page.
Dr. Purnanand Duddu Sarma is the Pres, CEO & Director at Immunome.
As the Pres、 CEO & Director of Immunome, the total compensation of Dr Sarma at Immunome is 657,442$. There are no executives at Immunome getting paid more.
Dr Sarma is 56, he's been the Pres、 CEO & Director of Immunome since . There are 2 older and 1 younger executives at Immunome. The oldest executive at Immunome, Inc. is Dr. Dennis H. Giesing, 69, who is the Chief Devel. Officer.
Purnanand's mailing address filed with the SEC is C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON, PA, 19341.
Over the last 4 years, insiders at Immunome have traded over 0$ worth of Immunome stock and bought 480,004 units worth 5,722,735$ . The most active insiders traders include Clay B Siegall、Jean Jacques Bienaime、Michael Rapp. On average, Immunome executives and independent directors trade stock every 84 days with the average trade being worth of 518,362$. The most recent stock trade was executed by Jean Jacques Bienaime on 15 August 2024, trading 7,000 units of IMNM stock currently worth 97,580$.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Immunome executives and other stock owners filed with the SEC include: